Member Info for Hits55

Jesse come across really well.

Rapid growth opportunities in biometrics.

Busy day today but nice and steady here

Https://www.linkedin.com/posts/physiomics-plc_translationalmodelling-modelinformeddrugdevelopment-activity-7466035650044080128-ssrL?utm_source=social_share_send&utm_medium=android_app&rcm=ACoAAEvHuYwBszXQW7zk1t8xmTsTpFbe6vTpv34&utm_campaign=whatsapp

Physiomics Demonstrates Hantavirus Translational Modelling Capability

Published on 05/28/2026

Physiomics plc highlighted the development of a hantavirus translational modelling framework demonstrating the Company's quantitative pharmacology and mechanistic modelling capabilities within infectious disease applications. The framework illustrates how Physiomics can integrate multiple evidence layers into a coherent translational workflow, linking in vitro antiviral screening, concentration-response potency modelling, pharmacokinetic exposure translation, mechanistic PK/PD viral dynamics, and virtual population simulations. The modelling workflow has been designed to demonstrate how quantitative systems pharmacology approaches may be used to assess whether antiviral activity observed in laboratory systems could plausibly translate into meaningful viral suppression under simulated human exposure conditions.

Illustrative workflow components include simulated 384-well phenotypic antiviral screening, EC50 and Emax concentration-response modelling, human PK exposure simulations against potency-linked targets, mechanistic viral-load dynamics modelling across differing antiviral modalities, and virtual population and time-to-clearance simulations. The Company believes the framework demonstrates the breadth and flexibility of Physiomics' modelling capabilities and highlights the potential role of mechanistic translational modelling in supporting infectious disease therapeutic development programmes. The material has been prepared for scientific and illustrative purposes only and does not constitute evidence of clinical efficacy for any specific therapeutic compound, nor has there yet been any commercial application of the hantavirus modelling framework.

The Company notes that further experimental, preclinical and clinical data would be required before any conclusions regarding therapeutic efficacy could be drawn.

Physiomics Demonstrates Hantavirus Translational Modelling Capability | MarketScreener https://share.google/syPn3A0mWxSdD65vg

Same comments

Same narrative

Different outcome

The new team are clearly showing that!

Skin in the game

Larger contracts

Better news flow

I understand that people come on here populated a negative narrative for many reasons and its not for the good of our health, had I have listened I would not be in profit.

Look at Kendrick, the Executive director here had 7% of it, if we can do 10% of that rise we will all be very very happy.

Physiomics is going places.

Key to the news is the comments by both our internal team Dr Aljayyoussi and comments by Pennington endorsing the work. More interesting is the speed in which the news is being delivered.

As step change in focus, but an acute focus on both utilisation of external opportunities with contract news in addition to new inroads to major institutions like Liverpool School of Tropical Medicine.

Great week so far

Https://www.physiomics.co.uk/hanta/

Same names continually finding clever veiled ways to have a pop at the company, yet the price continues to go higher, the absence of trying level the old complaints at a completely new team, with strong leadership in Stewart Williams is a pertinent step forward. Given he leads a $2bn contract for AZ I would argue at £3m quid mktcap, £750k+ arguably in the Bank coupled to strong revenue growth.

We're in a hit space (not just the UK this week :-)

Physiomics shares jump 18% after securing £345,000 in new contracts

https://www.proactiveinvestors.co.uk/companies/news/1092944/physiomics-shares-jump-18-after-securing-345-000-in-new-contracts-1092944.html

18%+

on google finance paying 0.75p

The awards comprise a combination of new and follow-on engagements with respected UK and international biotechnology and oncology-focused organisations, including a NASDAQ-listed clinical-stage biotechnology company, clinical-stage therapeutics developers, and leading cancer research groups. The contracts further reinforce Physiomics' growing reputation as a trusted scientific partner across the biotech and pharmaceutical sectors.

15%+

0.70-0.75 strong open

0.70-0.75 strong open

Hard to ignore over £345,000

Thats 1/3 of the annual revenues announced in a single piece of news within a month of new management, new AstraZeneca guy, new outreach,Pete staying and commenting positively.

You can sense the change in direction from the strong support in the stock price, this RNS helps to validate the growing confidence.

Sun is shining and the weather is hot (week off)

Queue AstraZeneca Stewart Williams who leads the $2bn AXIAL programme and Physiomics latest addition and Biometrics specialist Jesse Thissen (formerly of AZ)

Based on a 30-40bn market does this sound familiar to Physiomics PLC? This is breaking industry news, reviewing the acceleration of opportunities to providers.

Extract:

However, the services segment is expected to grow at a rapid CAGR during the forecast period, driven by the growing need for contract research, implementation support, and specialized consulting services. The ability to provide integrated solutions with expert support makes services highly attractive for modern pharmaceutical infrastructure

Rapid expansion:

Article below to read.

Biosimulation Market Research and Global Forecast Report 2026-2036: Expansion Driven by Precision Medicine, AI-Powered In-Silico Drug Development and Rising Demand for Cost-Efficient Clinical Trials https://share.google/Yh0r48pC9KCJIewmU

Another long day and weekend for me, but I'll keep following, it's reassuring to hear the team are together over a 2 day period. Why?

Things falling into place and sub £3m market capitalisation, trading two times revenues peeps.

Doseme updates, A.I awareness and strong outlook. If the chart breaks out completely, could 2p come quicker than expected?

I can't wait to see next steps.

Go well Team PYC

Kids makes a valid point, company functioning well, team all happy to work under new leadership, new additions and obvious strengths being identified.

Feels like we're heading towards stronger markets in the biotech/small pharma space too!

Brilliant update, showing new and old board member working together to forge a brighter future.

Hats off to Peter S